Charles River Enhances Oncology Services by Finalizing Acquisition of Piedmont Research Center
June 1, 2009 – On May 5, 2009, we completed our acquisition of North Carolina-based Piedmont Research Center, LLC. (PRC), which provides non-GLP efficacy studies in cancer pharmacology as well as other in vivo, in vitro, and analytical services. PRC will continue to operate from its North Carolina headquarters and will significantly expand the oncology expertise offered through our existing Discovery and Imaging Services. For the full press release, click here.
As the research and development efforts of our clients are increasingly aligned by therapeutic areas, we believe it is critical for us to provide deep expertise in their key areas of focus. Through our Discovery and Imaging Services, which now includes both PRC and MIR Preclinical Services (acquired in 2008), we offer non-GLP in vivo pharmacology, imaging, pharmacokinetics, and toxicology services to advance your lead candidate selection. Our therapeutic areas of expertise include oncology, cardiovascular, metabolism, and inflammation, among others, which represent four of the largest areas of biopharmaceutical research and development.
To learn more about how our non-GLP efficacy, pharmacokinetic, and toxicity evaluations can help advance your lead candidate selection, please contact us at 1.877.CRIVER.1 (1.877.274.8371) or askcharlesriver@crl.com, or visit www.criver.com/info/discoveryservices.
Related Information